A Phase 3 trial of oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China.

Trial Profile

A Phase 3 trial of oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2016

At a glance

  • Drugs Contezolid (Primary) ; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2016 According to a MicuRx media release, results from this trial are expected in 218.
    • 20 Oct 2016 According to a MicuRx media release, status changed from planning to recruiting.
    • 07 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top